NASDAQ:INDP Indaptus Therapeutics Q1 2026 Earnings Report $3.55 -0.38 (-9.67%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.68 +0.14 (+3.80%) As of 09/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Indaptus Therapeutics EPS ResultsActual EPS-$0.23Consensus EPS -$1.87Beat/MissBeat by +$1.64One Year Ago EPSN/AIndaptus Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIndaptus Therapeutics Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETUpcoming EarningsIndaptus Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Indaptus Therapeutics Earnings HeadlinesIndaptus Therapeutics Shares Rise After Entering $24 Million Private PlacementSeptember 10, 2026 | finance.yahoo.comIndaptus Therapeutics Announces Routine Board Member ResignationSeptember 4, 2026 | tipranks.comElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.September 20 at 1:00 AM | Paradigm Press (Ad)Indaptus Updates ATM Agreement to Expand Capital FlexibilitySeptember 1, 2026 | tipranks.comIndaptus Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update August 13, 2026 | quiverquant.comQIndaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 13, 2026 | globenewswire.comSee More Indaptus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email. Email Address About Indaptus TherapeuticsIndaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response. Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies. Its technology may also have applications in infectious diseases and other conditions where immune-system activation could provide a therapeutic benefit. Indaptus Therapeutics is headquartered in New York and conducts research and clinical development activities through its biotechnology programs. The company’s work remains focused primarily on advancing its investigational immunotherapy candidates through clinical development and establishing their potential use across oncology and related therapeutic areas.View Indaptus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
